European Psychiatry - Volume 33 - March 2016

717 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S713
EV1139
Depressive syndrome in
schizophrenia and cannabis use
S. Bouri ∗, H. zemmama , K. El Ayoubi , M.A. Berraho ,
A. Abdellaoui , S. Achour , I. Rammouz
1 Faculty of Science, Dhar El Mahraz, Laboratory Physiology,
Pharmacology & Environmental Health, Fez, Morocco
2 Faculty of medicine, Clinical neurosciences laboratory, Fez, Morocco
3 Faculty of medicine, Epidemiology Public Health, Fez, Morocco
4 Faculty of Science, Laboratory Physiology,Pharmacology &
Environmental Health, Fez, Morocco
5 University Hospital Hassan II, Toxicology Unit, Fez, Morocco
∗ Corresponding author.
Introduction Cannabis use is frequently observed in schizophre-
nia. Several medical and organic factors can lead to this
comorbidity. These include depressive symptoms.
Objective Assessing the prevalence of depressive symptoms
within a population of schizophrenic inpatients and the association
with cannabis use.
Method A group of 403 patients diagnosed with schizophrenia
according to Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV), were assessed by The Calgary Depression
Scale for Schizophrenia (CDSS) scale measure depressive symptom
in schizophrenia. Socio-demographic, clinic, and urine toxicology
screens testing data were collected.
Results The Schizophrenic patients included in this study have
an average age of 33 years. The majority of them are males (90%),
single (76%) and unemployed (72%). A total of 38 patients (9,4%)
have depressive symptoms (scored 6 or more on the CDSS). Among
this group, 16 patients (42,1%) were tested positive for cannabis
used. Although there is a high proportion of cannabis use among
patients with depression symptoms, there was no significant cor-
relation between the CDSS total score and cannabis use among
schizophrenic patients.
Conclusion Depression is well known to occur during the course
of schizophrenia in many patients and contributes substantially to
the morbidity. Studies are needed that include correlation analyses
between depression and cannabis use in schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1140
A comprehensive systematic
screening protocol for assessment of
medical comorbidities in
schizophrenia
P. Bucci ∗, E. Durante Mangoni , P.C. Pafundi , S. De Simone ,
U. Malgeri , A. Mucci , S. Galderisi , M. Maj
1 University of Naples SUN, Department of Psychiatry, Naples, Italy
2 University of Naples SUN, Internal Medicine Section, Department of
Cardiothoracic Sciences, and Division of Infectious and Transplant
Medicine, Naples, Italy
∗ Corresponding author.
Introduction Difficult access and low quality of health care are
recognized as factors that may account for the excess deaths widely
reported in patients with schizophrenia. As a matter of fact, psychi-
atrists not always possess adequate competences in the assessment
of physical health, while non-psychiatric physicians receive little
training in psychiatry and are not prepared to take care of subjects
with severe mental illnesses.
Objectives We present a comprehensive and systematic algo-
rithm for screening medical comorbidities, conceived to be easy
to use for psychiatrists, after a brief training.
Aims The study is aimed to implement an instrument for proper
detection and management of physical illnesses in people with
schizophrenia.
Methods The screening protocol, developed by internal medicine
specialists, was applied to 15 subjects in two independent assess-
ments, one performed by trainees in psychiatry, after a brief
training, and one carried out by one specialist and two trainees
in internal medicine. The analysis of the inter-rater reliability was
carried out by calculating the Cohen’s kappa coefficient and the
intraclass correlation coefficient as appropriate.
Results The agreement among raters resulted excellent for 61%
of items, good for 17%, moderate for 18% and scarce for 4%. The few
items showing scarce inter-rater reliabilitywere excluded. The final
algorithm is being tested for feasibility in psychiatric settings.
Conclusions The proposed screening protocol resulted in a suit-
able tool, showing moderate to excellent inter-rater reliability, that
can be used in clinical practice by psychiatrists after a brief training.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1141
Depot aripiprazole as an alternative to
the oral formula
M.R. Calero Fernandez
Hospital Gutierrez Ortega, Unidad de Salud Mental, Valdepenas,
Spain
Background Aripiprazole depot was launched in Spain in March
2015. American double blind studies with placebo showed a signif-
icant delay in relapse and a good tolerance profile with injectable
aripiprazole, with similar results to those obtained in studies com-
paring placebo and paliperidone depot.
Objective To compare the self-perceived changes after de substi-
tution of oral paliperidone to depot formula.
Type of study Descriptive, case series.
Sample Ten patients. Age range: 22–62 years (mean age:
41.2 years). Seven men + 3 women. Inclusion criteria: diagnosis
of schizophrenia or schizoaffective disorder, no acute psychotic
symptons. Prior treatment with oral aripiprazole (average dose:
17.5mg) 20% on monotherapy of aripiprazol Oral aripiprazol was
switched to the deport formula; 60% received a dose of 400mg/28
days and 40% received 300mg/28 days intramuscularly.
Results One patient abandoned the treatment after the first injec-
tion. Instrument for Assessment: IAQ scale: consists of 10 items;
we did not consider the items “prolactin level” and “akathisia” (no
patient showed neither before or after the treatment). The items
were rated by the patient: 1 (much better thanwith oral treatment),
2 (somewhat better), 3 (equal), 4 (worse) and 5 (much worse) aver-
ages scores: Positive symptoms: 1.25 Negative Symptoms: 1.75
Drowsiness: 1875 Weight gain: 1.625 extrapyramidalism: 1.875
Cognition: 1.625 Energy: 1.5 mood: 1625 total score media: 13.25
out of 40 (corresponding to the worst maximum score), 1.65 aver-
age per item.
Conclusion Depot aripiprazole can be an alternative to the oral
formula. The sample showed a self perceived improvement of their
general state from “much better” to “somewhat better” than with
oral treatment.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.